Aster DM Unit Buys Stake in STS Holdings for $44.1 Million

MUMBAI — Aster DM Quality Care Limited (formerly Aster DM Healthcare Limited) announced on Friday, August 28, 2026, that its Mauritius-based subsidiary, Chemistry Intermediate Holdings Limited, has completed the acquisition of a strategic equity stake in Bangladesh-based healthcare operator STS Holdings Limited for USD 44.11 million (approx. ₹370 crore).

The corporate transaction was detailed in a formal regulatory filing submitted to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Under the terms of the transaction, Chemistry Intermediate Holdings Limited acquired 22,727,584 equity shares, representing a 14.21 percent shareholding in STS Holdings Limited. The cash deal aligns with a broader Merger Framework Agreement initially signed in November 2024 and sanctioned by the National Company Law Tribunal (NCLT) in June 2026.

Merger Framework and NCLT Approval Context

The strategic investment in STS Holdings Limited forms part of Aster DM Quality Care’s ongoing cross-border corporate consolidation across South Asia.

According to the regulatory disclosure, the purchase executes terms set out in the Merger Framework Agreement executed on November 29, 2024, involving Quality Care India Limited, Aster DM Healthcare Limited, Dr. Azad Moopen, Union Investments Private Limited, Union (Mauritius) Holding Limited, BCP Asia II Topco IV Pte. Ltd., Centella Mauritius Holdings Limited, and Sri Sainatha Multispeciality Hospitals Private Limited.

The acquisition follows the approval of the Scheme of Amalgamation between Quality Care India Limited and Aster DM Healthcare Limited, which was granted by the Hon’ble National Company Law Tribunal (NCLT), Hyderabad Bench, via its judicial order dated June 19, 2026.

Target Profile and Financial Execution Details

STS Holdings Limited is a major healthcare services and medical training provider operating within Bangladesh. Incorporated on August 28, 1997, the target company reported continuous turnover growth over the past three fiscal years:

• FY 2023–24: BDT 7,777.02 million

• FY 2024–25: BDT 8,902.80 million

• FY 2025–26: BDT 10,534.24 million

The transaction cost stood at USD 44,114,339, executed via standard cash consideration. The acquisition price per equity share was structured at the USD equivalent of BDT 273.45 (Bangladesh Taka Two Hundred Seventy-Three point Four Five) for shares having a face value of BDT 10 each.

Aster DM Quality Care confirmed that the transaction does not fall under related party provisions, and neither the promoter nor promoter groups hold any direct interest in the acquired entity.

Strategic Impact on Regional Healthcare Expansion

The acquisition strengthens Aster DM Quality Care’s regional network by expanding its direct operational footprint in Bangladesh's growing healthcare market.

For investors, the acquisition enhances product offerings in tertiary healthcare and specialized clinical training across South Asia. Consumers and patients in Bangladesh and surrounding territories stand to benefit from capital infusion into medical infrastructure, diagnostic resources, and clinical services as STS Holdings Limited scales its operations alongside the integrated healthcare network.

Official Sources

According to official regulatory filings submitted to the BSE Limited and the National Stock Exchange of India Limited (NSE) on August 28, 2026, by Company Secretary Hemish Purushottam on behalf of Aster DM Quality Care Limited, the transaction details comply with the SEBI Master Circular guidelines issued on January 30, 2026.

Quote Section

"According to officials from Aster DM Quality Care Limited, the strategic acquisition of equity shares in STS Holdings Limited by Chemistry Intermediate Holdings Limited is executed in accordance with the Merger Framework Agreement and court-approved scheme of amalgamation."

Why It Matters

The investment expands Aster DM Quality Care's footprint into the high-growth Bangladesh healthcare market. It reflects a continuing trend of healthcare consolidation in South Asia following regulatory and court approvals. For public market investors, the USD 44.1 million cash investment demonstrates the group's post-merger balance sheet deployment strategy without creating related-party exposure.

Key Facts at a Glance

• Transaction Valuation: Chemistry Intermediate Holdings Limited bought equity shares in STS Holdings Limited for USD 44.11 million (approx. ₹370 crore).

• Equity Stake Acquired: 22,727,584 equity shares representing a 14.21% stake in STS Holdings Limited.

• Share Price: USD equivalent of BDT 273.45 per share against a face value of BDT 10.

• Target Company Performance: STS Holdings Limited recorded a turnover of BDT 10,534.24 million in FY 2025–26.

• Legal Authorization: Executed following NCLT Hyderabad Bench approval of the Scheme of Amalgamation on June 19, 2026.

Frequently Asked Questions

What company did Aster DM Quality Care acquire a stake in?

Aster DM Quality Care's subsidiary, Chemistry Intermediate Holdings Limited, acquired a 14.21 percent stake in STS Holdings Limited, a Bangladesh-based healthcare operator.

How much did the acquisition cost?

The total acquisition cost was USD 44,114,339, paid as cash consideration for 22,727,584 equity shares.

What is the financial background of STS Holdings Limited?

STS Holdings Limited recorded turnover growth over three consecutive years, rising from BDT 7,777.02 million in FY 2024 to BDT 10,534.24 million in FY 2026.

Did the deal require special court approvals?

Yes, the transaction forms part of the Merger Framework Agreement disclosed in the Scheme of Amalgamation between Quality Care India Limited and Aster DM Healthcare Limited, approved by the NCLT Hyderabad Bench on June 19, 2026.

Source: Official corporate regulatory disclosures submitted to BSE Limited and National Stock Exchange of India Limited by Aster DM Quality Care Limited on August 28, 2026.